• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Johnson & Johnson pharma sales drive Street-beating Q4 results

Johnson & Johnson pharma sales drive Street-beating Q4 results

January 26, 2021 By Chris Newmarker

Johnson & JohnsonJohnson & Johnson (NYSE:JNJ) posted fourth-quarter results today that beat the consensus forecast on Wall Street — with the company predicting a return to strong sales growth in 2021.

The New Brunswick, N.J.–based pharma, medical device and consumer products giant reported profits of $1.7 billion, or 65¢ per share, on sales of $22.5 billion for the three months ended Dec. 29, 2020, for a bottom-line decline of –56.7% on sales growth of 8.3% compared with Q4 2019.

Adjusted to exclude one-time items, earnings per share were $1.86, 4¢ ahead of The Street, where analysts were looking EPS of $1.82 on sales of $21.7 billion.

CEO Alex Gorsky said in a news release that the company is leading in the fight against COVID-19.

“We continue to progress our COVID-19 vaccine candidate and look forward to sharing details from our Phase 3 study soon,” Gorsky said. “Johnson & Johnson was built for times like these, and I am extremely confident in our ability to deliver lasting value and continued innovation in 2021 and for years to come.”

CFO Joseph Wolk told CNBC that vaccine study results will be available early next week, with the company on track to provide the U.S. with 100 million doses by the end of June.

J&J expects to log adjusted earnings per share of $9.40–$9.60 this year, a 17.1%–19.6% increase over 2020, with sales growth of 9.5%–11.0% bringing in $90.5–$91.7 billion in revenue. Wall Street analysts on average had predicted earnings per share of $8.99 off $89 billion in 2021.

Investors reacted by sending JNJ shares up 2.6% to $1.70 apiece today in morning trading. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was down slightly.

Pharma business sales were up 16.3% year-over-year, to $12.3 billion, in Q4, driving overall growth. Overall U.S. drug sales fell in the same period. Revenue-driving drugs — highlighted during today’s earnings call — treated diseases ranging from Crohn’s disease to cancer to hypertension:

  • Stelara (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases such as Crohn’s disease, was up 30.3%;
  • Darzalex (daratumumab), for the treatment of multiple myeloma, grew 49%;
  • Imbruvica, an oral, once-daily therapy approved for treating a certain type of blood or lymph node cancer, was up 25.3%;
  • Erleada (apalutamide), a next-generation androgen receptor inhibitor for treating prostate cancer, saw strong growth momentum;
  • Tremfya (guselkumab), a biologic for the treatment of adults with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis, grew 39.3%;
  • Invega Sustenna/Xeplion/Invega Trinza/Trevicta (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of adult schizophrenia;
  • Opsumit (macitentan), an oral endothelin receptor antagonist to treat pulmonary arterial hypertension and delay disease progression, was up 36.7%;
  • Uptravi (selexipag), an oral prostacyclin receptor agonist to treat pulmonary arterial hypertension and reduce hospitalization, grew 44.1%.

Medical device sales ticked down –0.7% year-over-year, to $6.6 billion, in Q4 as the pandemic continues to cause hospitals as well as patients to defer medical procedures. Wolk during his talk with CNBC predicted a big Q2 for J&J’s medical device business.

The company’s DePuy Synthes ortho business last week announced FDA clearance for Velys, a robotic-assisted system designed for use with the Attune total knee system — part of J&J’s strategy to more actively compete against Stryker and its popular Mako ortho surgery robots.

“This is a market that … we think has a significant opportunity for growth in terms of penetration. We also think it will be a nice complement to our Attune fixed bearing cementless knee. And remember, we also have plans to expand Velys significantly beyond just knee replacement but to other areas as well,” Gorsky said during today’s earnings call.

J&J unveiled its next-generation Ottava soft tissue robotic surgery system in November. Gorsky told analysts: “We truly think it’s going to offer a next-generation digital and robotic surgery.”

 

Filed Under: Business/Financial News, Featured, Wall Street Beat Tagged With: Johnson & Johnson, Johnson and Johnson

In case you missed it

  • Ambu replaces CEO with new leadership
  • Moderna’s first bivalent COVID-19 vaccine booster candidate shows promise
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
  • FDA clears Accelus’ Toro-L interbody fusion system
  • Teleflex’s UroLift cleared in China to treat BPH
  • Globus Medical announces first surgeries with Excelsius3D
  • Abbott reports positive data on heart valve therapies
  • OncoRes Medical raises another $12.5M
  • NeuroMetrix’s Quell neuromodulation device wins FDA de novo nod to treat fibromyalgia
  • Inogen appoints Agnes Lee as senior VP of investor relations, strategic planning
  • Google Health hires FDA’s chief digital health officer
  • ApiJect picks up $111M investment from Royalty Pharma, Jefferies
  • Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says
  • Teleflex wins Health Canada nod for Manta vascular closure device
  • Study shows strong performance, improved outcomes with Medtronic Evolut TAVR
  • New FDA clearance expands indications for Xact Robotics’ ablation system
  • Medtronic’s Resolute Onyx drug-eluting stent demonstrates strong safety, efficacy

RSS From Medical Design & Outsourcing

  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
    BD (NYSE:BDX) announced that it partnered with Mitsubishi Gas Chemical Company on applying new technology to pre-fillable syringes. MGC develops the Oxycapt technology designed to integrate the best of plastic and glass for plastic syringes. BD and Tokyo-based MGC will work together to apply Oxycapt technology to the next generation of pre-fillable syringes (PFS) for advanced… […]
  • Ambu replaces CEO with new leadership
    Ambu today said it has hired board member Britt Meelby Jensen to replace CEO Juan Jose Gonzalez, effective tomorrow. “Since Juan Jose Gonzalez joined as CEO in 2019, Ambu has made good progress and achieved important milestones on the strategic transformation into the world’s largest single-use endoscopy company,” Ambu Chair Jørgen Jensen said in a… […]
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
    AdvaMed executive Abby Pratt has joined the executive committee for the Biden administration’s Joint Supply Chain Resilience Working Group, the medtech industry association said today. The working group’s members from government and industry will assist with implementation of the National Strategy for a Resilient Public Health Supply Chain. Pratt oversees supply chain issues as SVP… […]
  • Toray develops new stretchable film for medical devices
    Toray Industries has a new stretchable film based on its proprietary polymer Reactis technology, with potential applications that include robotics and biological and industrial sensors. Tokyo-based Toray said it shipped samples to customers and plans research and development efforts to commercialize the new grade of film. “Recent years have increased the potential for developing stretchable… […]
  • Google Health hires FDA’s chief digital health officer
    Former FDA Chief Digital Health Officer of Global Strategy and Innovation Bakul Patel has started a new job with Google after 13 years with the regulatory agency. Patel became senior director, global digital health strategy and regulatory for Google Health earlier this month, he said on LinkedIn. Patel recounted highlights of his “incredible journey since… […]
  • Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says
    Two years into the COVID-19 pandemic, we know more than ever about the SARS-CoV-2 virus and how quickly it moves to ravage the human body. What remains to be seen is how the virus — and perhaps more importantly, our immune system’s response to it — will affect the health of people long after infection,… […]
  • FDA moves forward with Voluntary Improvement Program to bolster medical device quality
    Kathryn Burke, Emergo Group The U.S. Food and Drug Administration has issued new draft guidance to establish a full-blown voluntary program for improving quality-related processes in medical device manufacturing following promising results of a pilot program. The FDA guidance stems from a pilot undertaken by the agency along with the Medical Device Innovation Consortium (MDIC) in 2018.… […]
  • How Minnetronix Medical helped Lazurite with its wireless surgical camera
    Minnetronix Medical (St. Paul, Minnesota) has played an important development and manufacturing partner role with Lazurite’s wireless surgical camera system. It’s been nearly two months since Lazurite (formerly Indago) announced FDA 510(k) clearance of its ArthroFree system. ArthroFree combines proprietary low-heat, high-intensity Meridiem light engine technology with advanced camera, battery and wireless transmission technologies and… […]
  • Instron releases TrendTracker data analysis workflow platform
    Instron announced that it released the TrendTracker module in Bluehill Central for accelerating data analysis workflows. Norwood, Massachusetts-based Instron designed TrendTracker with an intuitive interface to improve the data analysis workflow of single or multi-location materials testing laboratories. According to a news release, the platform features quick searching and the ability to display and analyze… […]
  • Henry Schein hires former Medline veteran to drive ‘One Distribution’ push
    Henry Schein (Nasdaq:HSIC) today named Dirk Benson as VP and chief commercial officer of the medical device manufacturer and distributor’s North America Distribution Group (NADG). Melville, New York-based Henry Schein is the world’s largest provider of health care supplies and services for office-based dental and medical practitioners, and NADG is the company’s largest business group. The… […]
  • The road to a robot: Medtronic’s development process for its Hugo RAS system
    Elephants are the perfect analogy for surgical robotics, Medtronic (NYSE:MDT) VP of Marketing for Surgical Robotics Mike Stow says. Speaking on the “Road to a robot: Designing technology to address unmet needs & barriers” panel at DeviceTalks Boston last week, Stow explained that elephants are big, taking up a lot of space and that they eat a lot, making… […]

Primary Sidebar

DeviceTalks Weekly

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS